FindTrial
Sign In

Personalized neoantigen tumor vaccine

BIOLOGICAL6 trials

Sponsors

YueJuan Cheng, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Acute Myeloid LeukemiaAdvanced Pancreatic CancerAdvanced Solid TumorB-cell Non-Hodgkin's Lymphoma (B-NHL)Chemotherapy-intolerantPancreatic Cancer ResectableSolid Tumor

Early Phase 1

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
RecruitingNCT05916248
Ruijin HospitalAdvanced Solid Tumor
Start: 2023-12-20End: 2026-12-30Target: 34Updated: 2025-04-01
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
RecruitingNCT05916261
Ruijin HospitalAdvanced Pancreatic Cancer
Start: 2023-04-26End: 2026-12-30Target: 54Updated: 2023-10-26
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
RecruitingNCT06496373
Ruijin HospitalChemotherapy-intolerant, Pancreatic Cancer Resectable
Start: 2024-07-16End: 2027-06-30Target: 20Updated: 2025-11-17
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
RecruitingNCT06980155
Shanghai Jiao Tong University School of MedicineAcute Myeloid Leukemia
Start: 2025-05-30End: 2028-08-30Target: 60Updated: 2025-05-20

Phase 1

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
Not yet recruitingNCT07334574
Ruijin HospitalB-cell Non-Hodgkin's Lymphoma (B-NHL)
Start: 2026-01-15End: 2029-01-01Target: 20Updated: 2026-01-13

Unknown Phase

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors
NCT05359354
YueJuan ChengSolid Tumor
Start: 2022-09-01End: 2025-12-31Target: 36Updated: 2023-05-16

Related Papers

An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.
Journal of Clinical Oncology2026-05-27